Astrazeneca Plc (AZN.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Sales | 58,739,000 | 54,073,000 | 45,811,000 | 44,351,000 | 37,417,000 |
| Cost of Goods | 10,633,000 | 10,207,000 | 8,268,000 | 12,391,000 | 12,437,000 |
| Gross Profit | 48,106,000 | 43,866,000 | 37,543,000 | 31,960,000 | 24,980,000 |
| Operating Expenses | 34,779,000 | 33,615,000 | 28,821,000 | 27,399,000 | 25,114,000 |
| Operating Income | 13,327,000 | 10,251,000 | 8,722,000 | 4,561,000 | -134,000 |
| Interest Expense | 1,614,000 | 1,682,000 | 1,589,000 | 1,330,000 | 1,276,000 |
| Other Income | 689,000 | 122,000 | -234,000 | -730,000 | 1,145,000 |
| Pre-tax Income | 12,402,000 | 8,691,000 | 6,899,000 | 2,501,000 | -265,000 |
| Income Tax | 2,169,000 | 1,650,000 | 938,000 | -792,000 | -380,000 |
| Net Income Continuous | 10,233,000 | 7,041,000 | 5,961,000 | 3,293,000 | 115,000 |
| Minority Interests | -8,000 | -6,000 | -6,000 | -5,000 | -3,000 |
| Net Income | $10,225,000 | $7,035,000 | $5,955,000 | $3,288,000 | $112,000 |
| EPS Basic Total Ops | N/A | 4.54 | 3.84 | 2.12 | 0.08 |
| EPS Basic Continuous Ops | N/A | 4.54 | 3.84 | 2.12 | 0.08 |
| EPS Diluted Total Ops | N/A | 4.50 | 3.81 | 2.11 | 0.08 |
| EPS Diluted Continuous Ops | N/A | 4.50 | 3.81 | 2.11 | 0.08 |
| EBITDA(a) | $19,506,000 | $15,438,000 | $13,422,000 | $9,085,000 | $7,541,000 |